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Abstract 
Background
 
: Ovarian cancer has the highest mortality of all the gynecological cancers in women. 
It is the fifth leading cause of cancer death among women due to late stage clinical diagnosis 
when treatment options are less effective. An important limiting factor in the development of 
new and effective treatments is identification of a suitable animal model. Ovarian 
adenocarcinoma (OAC) occurs spontaneously in hens, as in women, and increases in prevalence 
with age. Ovarian adenocarcinoma in women and hens have similar histologic features, 
biomarker staining and epidemiological characteristics. Recently, human endogenous 
retroviruses (HERVs) have been shown to be associated with ovarian cancer in women. Hens 
also have endogenous retroviruses, notably Avian Leukosis Virus E (ALV-E). The link between 
ALV-E and OAC in hens has not been adequately investigated. ALV infection in hens can be 
diagnosed by detecting ALV antigen in serum using an antigen-capture ELISA. However, this 
test does not distinguish endogenous ALV-E from exogenous ALV subgroups. ALV-E can be 
specifically identified by detecting expression of Eenv in RNA isolated from tissues.  
Hypotheses: 1.The prevalence of ALV, Eenv mRNA expression, and OAC in aged birds in the 
University of Illinois Urbana-Champaign (UIUC) Poultry Research Laboratory laying flock is > 
5%. 2. Birds that have OAC are at increased risk of being positive for ALV by antigen capture 
ELISA than those that do not have OAC. 3. Birds that have OAC are at increased risk of 
manifesting expression of Eenv mRNA in their spleen than those that do not have OAC. 
Animals: 177 White Leghorn hens of three different age groups: 104 weeks old, 130 weeks old 
and ≥ 165 weeks old 
Methods: Hens were stratified by age and then randomly selected. Blood was withdrawn via 
jugular or cardiac venipuncture and the hens were humanely euthanized in a carbon dioxide 
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chamber and immediately necropsied. Tissues harvested included ovaries, spleens and any gross 
lesions. Tissues were fixed in 10% buffered formalin for histopathology. Serum was used to 
conduct the ALV ELISA and the spleen was used to extract RNA and perform RT-PCR to detect 
ALV-Eenv mRNA expression. 
Results: The overall prevalence of OAC was 22.6% with significant associations between OAC 
and age, and ALV and age. Hens with OAC were 5.2 times more likely to be ALV positive than 
hens without OAC, and hens with OAC in the 165-week age stratum were also 5.2 times more 
likely to be ALV positive then hens without OAC in this age stratum. ALV-Eenv mRNA 
expression was not uniformly expressed across the three age strata; there was a tendency for 
older hens and hens with OAC to be more likely to express ALV-Eenv mRNA. ALV-Eenv 
mRNA expression was associated with an increased risk of being ALV positive. Older hens and 
hens with OAC were more likely to express ALV-Eenv mRNA. 
Conclusions: This is the first time a viral infection has been associated with OAC in hens. 
Endogenous ALV-E in hens may be analogous to the HERV’s, which have been associated with 
OAC in women.  Since the risk of ALV, Eenv mRNA expression, and OAC all increased with 
age, additional studies are needed to determine causal relationships.  
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Chapter 1.  Introduction 
Ovarian cancer has had a devastating effect on women. In 2009, ovarian cancer 
was responsible for approximately 14,600 deaths and 21,550 new cases1 in the United 
States of America (USA). It is estimated that one in every 71 women will develop ovarian 
cancer with an overall lifetime risk of 1.5%2. Although ovarian cancer accounts for only 
5% of all cancers in women in the USA3, it has the highest mortality of all cancers of the 
female reproductive system4, and is the 5th leading cause of cancer death among 
women3, with a case fatality rate of approximately 68%3. Annual treatment costs for 
ovarian cancer in the USA are estimated to be $ 2.2 billion1.  
An important limiting factor in the development of new and effective treatments 
for ovarian cancer is the identification of a suitable animal model.  Women develop 
ovarian adenocarcinoma (OAC) spontaneously, which rarely occurs in most species 
except for rodents and chickens.  Various strains of mice and rats will spontaneously 
develop ovarian tumors of a wide variety of histological subtypes5, but do so at a very 
low prevalence and late in life. For this reason, these species are most often induced to 
develop OAC for research5. The laying hen develops OAC at a much higher prevalence 
with similar histologic features, biomarker staining and epidemiological characteristics to 
OAC in women and therefore can be used as a practical model without a need for 
artificial induction of the tumor. Recently, human endogenous retroviruses (HERVs) 
have been shown to be associated with ovarian cancer in women6. No viral risk factor 
thus far has been shown in hens to cause OAC. Avian Leukosis Virus subgroup E (ALV-
E) is an endogenous retrovirus of chickens that is considered to be non-pathogenic. 
However, with the discoveries of HERV’s and their association with OAC in women, we 
 2 
hypothesize that ALV-E may be analogous to HERVs, in that HERVs can be considered 
potential risk factors for ovarian oncogenesis. The Avian Leukosis group of viruses is 
well documented as being associated with a variety of oncogenic disorders, such as B-cell 
lymphoma/leukemia, erythroleukemia (erythroblastosis), myeloid leukemia 
(myeloblastosis or myelocytomatosis) and connective tissue tumors (fibrosarcoma, 
nephroblastoma, etc.)7-9. Recently, the emergence of exogenous infectious ALV-J has 
been shown to actually be a re-emergence of an endogenous strain of ALV-J (ev/J 4.1 
Rb)10. These findings, coupled with the finding that 2% of the chicken’s genome is 
comprised of endogenous retroviral DNA, with 11 new families of these viruses recently 
discovered11, indicates that  further investigation is needed  to determine the relationship 
between ALV-E  (and other ERV) and OAC. If there is a relationship, then this 
relationship will further augment the application of the hen as a model for OAC in 
humans. 
 The specific objectives of this thesis research project were: 
1. To determine the prevalence of OAC in aged birds in the UIUC poultry 
research laboratory laying flock. 
2. To determine the association between ALV and OAC in aged birds in the 
UIUC poultry research laboratory laying flock 
3. To determine the association between expression of ALV-E encoded mRNA 
and OAC in aged birds in the UIUC poultry research laboratory laying flock. 
1. The prevalence of ALV, ALV-Eenv mRNA expression, and OAC in aged 
birds in the UIUC poultry research laboratory laying flock is > 5%. 
Hypotheses 
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2. Birds with OAC are at increased risk of being positive for ALV  
3. Birds with OAC are at increased risk of manifesting expression of ALV- Eenv 
mRNA in their spleen than those that do not have OAC. 
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Chapter 2.  Literature Review 
Introduction  
 Ovarian cancer has had a devastating effect on women. The National Cancer 
Institute estimated that in the USA in 2009 there were 21,550 new cases of ovarian 
cancer diagnosed and 14,600 deaths due to ovarian cancer1.  One in every 71 women will 
develop ovarian cancer during their lifetime2. Although ovarian cancer accounts for only 
5% of all cancers in women in the USA3, it has the highest mortality of all cancers of the 
female reproductive system4.   With a case fatality rate of approximately 68%3, ovarian 
cancer is the 5th leading cause of cancer death among women3.  Annual treatment costs 
for ovarian cancer in the US are estimated to be $ 2.2 billion1.   
One important limitation for the development of new and effective treatments for 
ovarian cancer is the identification of a suitable animal model.  Spontaneous occurrence 
of OAC is rarely seen in most species.  Various strains of mice and rats will 
spontaneously develop ovarian tumors of a wide variety of histological subtypes5. 
Spontaneous onset of OAC in rodents typically begins at a later age and the rate of 
occurrence is very low5 making them suboptimal as models for experimental study of 
ovarian cancer in humans. One proposed explanation for this stems from the fact that 
ovarian carcinoma is associated with frequent ovulation12.  Adult female animals of most 
species, whether domestic or wild, are either persistently pregnant, lactating or seasonally 
anestrus.  These physiological states are not associated with ovulation and ovarian 
cancer13.   The domestic hen is an exception. 
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Hens show many similarities to humans related to the development of OAC. 
Hens, like women, are persistent ovulators and ovulate repeatedly for many years.  
Previous researchers have reported a 4% prevalence of spontaneous development of OAC 
in 2-yr-old hens14.  This prevalence increases with age15-17. Both women and hens 
normally have simple, squamous to cuboidal epithelium covering the ovarian surface, 
with epithelial cells demonstrating nuclear staining for progesterone receptors (PR)13. In 
both species, cells of ovarian tumors stain strongly for cytokeratin (marker for epithelial 
cells) and proliferating cell nuclear antigen (PCNA) (an indicator of mitotic activity)13. 
Epidemiologic data suggest that progesterone may confer some protection from ovarian 
cancer in women18, and treatment with progestin in hens has been correlated with a 
reduced incidence of the disease14. 
It is because of these similarities to women that several studies have used 
domestic hens as a research model for human OAC13,15,17,19,20. Human endogenous 
retroviruses have recently been associated with OAC in women6 and raise the possibility 
that endogenous retroviruses may also be associated with OAC in hens.  This literature 
review will compare and contrast the pathology and pathogenesis of OAC in women and 
hens, with particular attention to the current literature on the potential role of reverse 
transcribing retroviruses in OAC in both women and hens. 
 
Ovarian Adenocarcinoma: Pathology and Pathogenesis in Hens: Laying hens possess 
only one functional ovary – the left ovary (Figure 1), with the right ovary and oviduct 
regressing during embryonic development. In the normal laying hen, the ovary contains a 
hierarchy of pre-ovulatory follicles with the largest yolk- filled follicle (F1) destined to 
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ovulate first, and the second largest (F2) to ovulate the following day22.  Also observed 
on the normal ovary will be a number of small white and large yellow follicles.  
A normal healthy hen’s ovary has a layer of squamous to cuboidal epithelial cells 
on the surface13. The earliest histologically detectable structures of OAC, according to 
Fredrickson15, are small groups of cells forming round acini, either in the ovarian stroma 
or growing near or within the theca externa. In some cases, early acini somewhat 
resemble thecal gland cells. Individual acini often enlarge to line slit-like spaces, or a 
cribriform pattern may predominate.  In some tumors, individual acini are separated by 
wide bands of dense fibrous connective tissue. A characteristic of all forms of OAC is a 
single layer of low columnar or cuboidal cells surrounding lumens. Giles19 reported that 
ovarian tumors in hens were often composed of columnar or high cuboidal epithelial cells 
with basally situated nuclei and abundant eosinophilic cytoplasm. The nuclei were 
vesicular with prominent nucleoli in some areas. These cells tended to form nests as well 
as glands of various sizes, often accompanied by a desmoplastic reaction.  There were 
also atypical cells resembling squamous epithelial cells.  
  Ultrastructurally, the layer of cells surrounding the lumens of tubules and acini 
forms a tight adherent ring of cells joined along their apical borders by prominent 
desmosomes.  A prominent feature is the presence of short microvilli projecting into the 
acinar lumen, which contains a variable amount of moderately electron-dense material. 
The tumor may also contain groups of darkly staining cells within the ovarian stroma or 
loose clusters of cells attached to the cortical surface. Such cells appear to have 
undergone degeneration, with formation of cytoplasmic vacuoles and densely osmophilic, 
irregularly shaped cytoplasmic inclusions. Glandular forms of the tumor are also seen. 
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Infrequently nests of cells appear to have undergone some degree of squamous 
metaplasia, with intervening areas containing structures similar to acini with transitional 
forms in adjacent areas15.  Hens may also develop granulosa cell tumors and Sertoli cell 
tumors, but these occur less commonly.  
The normal ovulatory cycle consists of a follicular phase compressed into a 25-
27-hr period. During this brief period, subtle and stringently regulated release of 
gonadotropins (follicle stimulating hormone (FSH) and luteinizing hormone (LH))   
promote follicular development and maturation which culminate in ovulation22. During 
this period there is a decrease in FSH receptors in the ovarian granulosa cells with a 
concomitant increase of LH responsiveness of these cells. Many commercial strains of 
laying hens will ovulate almost daily through 1 or 2 years of egg production.   
Fredrickson15 classified ovarian tumors in the hen into 4 stages depending on their 
gross characteristics. In stage 1, the growths are nodular, very firm, white and closely 
resemble atretic follicles. Ovarian adenocarcinomas tend to be less symmetric than atretic 
follicles and may be buried within the ovarian stroma or growing on the surface of 
follicles (Figure 2). In stage 2, the growths increase in size and coalesce so that the ovary 
takes on the appearance of a cauliflower, and loses its maturing follicles. It is these 
ovaries that seed the abdominal cavity with tumor cells. When large numbers of 
individual foci grow on serosal surfaces of the oviduct, mesentery, intestines, and 
pancreas, the patient is at stage 3. In stage 4, growth of implanted cells appears to be 
rapid, with pronounced reaction of the muscularis of the oviduct and intestine.  The 
sequelae are contraction of the mesentery, bowel wall thickening, and ascites. As much as 
500mL of fluid may be present in the coelomic cavity. Cystic structures, filled with clear 
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to translucent, amber-colored fluid can project from the surface of the ovary. 
Fredrickson15 reported that these cysts are not tumorigenic but are associated with the 
development of OAC. 
More recently, Barua23 applied the tumor staging system used in women in 
accordance with the International Federation of Gynecology and Obstetrics (FIGO, Rio 
de Janeiro, 1988) to ovarian tumors of the hen. In stage I, the tumors were confined to the 
ovary, firm, and resembled cauliflower-like nodules with no or minimal accompanying 
ascites. In stage II, tumors had metastasized to the oviduct with occasional seeding of the 
pelvic sidewall and moderate ascites, and in stage III, tumors had metastasized to both 
abdominal and peritoneal organs including the small and large intestine, mesentery, 
abdominal undersurface of the diaphragm, and surface of the liver and there was 
moderate to profuse ascites. Lastly, in stage IV, there was evidence of carcinomatosis and 
massive ascites, and tumors had metastasized to most of the pelvic, abdominal, and 
thoracic organs including liver, spleen, and lung.  
 
Ovarian Adenocarcinoma: Pathology and Pathogenesis in Humans. The ovaries in 
women are paired, and the surface is generally smooth in early reproductive life, 
becoming more convoluted as the person ages1. In women, ovarian surface epithelium 
(OSE) covers the entire ovarian surface and varies morphologically from simple 
squamous to cuboidal to low pseudostratified columnar24. Embryologically derived from 
the mesodermal epithelium of the gonadal ridges, OSE cells are continuous with the 
flattened mesothelium of the peritoneum25 and are separated from the underlying stromal 
compartment of the ovary by a basement membrane. 
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 The process of ovulation is controlled by the hypothalamus through the release of 
gonadotropin releasing hormone (GnRH) from the hypothalamus, which stimulates the 
anterior lobe of the pituitary gland to secrete LH and FSH. In the follicular (pre-
ovulatory) phase of the menstrual cycle, the ovarian follicle undergoes a series of 
transformations that is stimulated by the secretion of FSH. Ovulation is triggered by a 
spike in the amount of LH released from the pituitary gland. Ovulation occurs during the 
follicular phase of the menstrual cycle, and is the transitionary period from the follicular 
phase into the luteal phase. This process (menstrual cycle) is 28 days in women.   
There are three major groups of ovarian tumors that occur in women.  The most 
commonly occurring type is epithelial derived tumors (85-90% of cases)26,  with germ 
cell and stromal tumors being less common. Stromal tumors tend to occur in younger 
women. Invaginations of the epithelium result in crypts or gland-like structures that can 
become pinched off to form epithelial inclusion cysts within the underlying stromal 
compartment27. This process may occur following the postovulatory proliferation of OSE, 
during follicular attrition, and/or as a result of inflammation caused by carcinogens or 
chemical irritants like talcum powder28. The incidence of inclusion cysts increases with 
advancing age and is common in postmenopausal women. Although generally benign in 
nature, these epithelial rearrangements are widely thought to be the potential origin of 
many epithelial cancers. The more frequent appearance of epithelial invaginations and 
inclusion cysts in women with a hereditary risk of ovarian cancer has strengthened this 
hypothesis29. In addition, some microscopic borderline malignant and malignant tumors 
have been observed to arise directly within these sites of epithelial rearrangements, and 
are often associated with dysplasia in the same or contralateral ovary30-31.  
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According to the "incessant ovulation hypothesis", continuous ovulation, with its 
repeated rounds of surface rupture and OSE cell mitosis to repair the wound, renders the 
cells susceptible to malignant transformation12. Godwin et al32and Roby et al33 
demonstrated evidence supporting this theory by illustrating the susceptibility of OSE 
cells to mutagenic events during mitosis in primary cultures of normal rat and mouse 
OSE cells which had been repeatedly subcultured to maintain continued proliferation. 
These cells acquired features associated with malignant transformation, including loss of 
substrate-independent growth, loss of contact inhibition, and the ability to form tumors in 
nude mice. Epidemiologic studies support the hypothesis by revealing that a decrease in 
the number of ovulations reduces the risk of ovarian cancer 18,34-35.   
Kurman and Shih36 proposed a new model for the pathogenesis of OAC based on 
clinical, pathological and molecular genetics by dividing ovarian tumors into two broad 
groups, designated Type I and Type II. Type I tumors are slow growing and generally 
confined to the ovary at diagnosis. They develop from well established precursor lesions 
that are termed “borderline” tumors. Type I tumors include serous carcinoma, mucinous, 
endometrioid, clear cell, and low-grade micropapillary carcinomas. They are genetically 
stable tumors and are characterized by mutations in a number of different genes including 
KRAS, BRAF, PTEN, and beta-catenin. In contrast, Type II tumors are rapidly growing, 
highly aggressive neoplasms for which well defined precursor lesions have not been 
described. The vast majority of what is considered “ovarian cancer” belongs to the Type 
II category. Tumors in this category include high-grade serous carcinoma, malignant 
mixed mesodermal tumors (carcinosarcomas), and undifferentiated carcinomas.  
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Recent development of molecular biomarkers has enhanced detection and 
prognosis of ovarian cancers in women. The following biomarkers are present in human 
OAC and also stained OAC in hens. These biomarkers include antibodies that detect 
cytokeratins (AE1/AE3, pan cytokeratin), growth factor receptors (EGFR, erbB-2) and 
oncofetal tumor markers (Lewis Y, CEA and Tag 72). More specifically, epidermal 
growth factors (EGFR, erbB-2) and p185 (a product of a proto-oncogene) stained tumor 
cells diffusely, while cytokeratins AE1/AE3 and pan cytokeratin and the onco-fetal tumor 
markers were focally positive in the tumor. Antibodies against proliferating cell nuclear 
antigen (PCNA- a proliferation marker), transforming growth factor alpha (TGF-α- an 
activating ligand present on the epidermal growth factor receptor), and p27 (a cell cycle 
inhibitor) have stained hen OAC and have been useful as surrogate endpoints in 
chemoprevention trials in women17. Biomarker antibodies for OAC in women that were 
not cross-reactive in the hen included CA 125, Ki-67, and Muc 117. 
CA 125 (cancer antigen or carbohydrate 125), also known as MUC16, is a protein 
that is most commonly expressed by the female reproductive tract (ovaries, endometrium, 
fallopian tubes), lungs, breast and gastrointestinal tract. Elevated levels of CA125 in the 
blood of some patients have been associated with specific types of cancers, but it is best 
known as a biomarker for ovarian cancer. However, its elevation is not exclusive to 
tumors as it can also be elevated in benign conditions such as endometriosis37 and 
pregnancy38. Up to 20% of OAC cases do not express CA 12539.  Ki-67 is a marker 
strictly for cell proliferation, but it is also found in normal tissues. However, the fraction 
of Ki-67 positive tumor cells (known as the Ki-67 labelling index) is mostly associated 
with carcinomas of the prostate and breast. Lastly, Muc 1 is a mucin that penetrates 
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membranes of epithelial cells, and protects the body from infection by binding to 
pathogens.  Over-expression, aberrant intracellular localization and changes in 
glycosylation of Muc1 have been associated with carcinomas especially of the colon40.     
Another protein of interest is ovalbumin, which is the major protein formed in 
normal oviductal tissue of hens. Giles et.al19 found that hens diagnosed with 
adenocarcinoma of the ovaries expressed ovalbumin in the ovary.  They reported the 
presence of ovalbumin in 100% of hen ovaries with OAC in the absence of any oviductal 
involvement. This finding suggests that ovarian tumors may de-differentiate during the 
disease process and acquire characteristics of Mullerian duct-derived epithelia, a 
phenomenon that has also been described in women41. Thus, in this respect, ovarian 
tumors in the hen, and epithelial derived OAC in women show similar behavior, further 
supporting the claim that the laying hen is a good model for OAC in women. 
 
Epidemiology of Ovarian Adenocarcinoma. Several specific risk factors have been 
identified for OAC in women. Inherited gene mutations, such as mutations of BRCA1 
and BRCA2, were originally identified in families with multiple cases of breast cancer. 
However, women with these mutations also have a significantly increased risk of 
developing OAC.  Other risk factors include a family history of OAC not due to any 
known gene alterations, and a personal history of breast cancer. Age has also proven to 
be a significant risk factor, in that OAC develops most often in postmenopausal women, 
with the risk increasing with age into the late 70’s. Women who have had at least one 
pregnancy or have used oral contraceptives have lower risks of developing OAC. 
Infertility increases the risk of OAC, whether due to the pathology that led to infertility or 
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due to the use of fertility drugs. Hormone replacement therapy (HRT) in postmenopausal 
women, especially with estrogen-only therapies42, increases the risk of OAC. Being obese 
also increases both the risk of OAC and the aggressiveness of the tumors. The use of 
androgens, such as danazol43 which is used to treat endometriosis, may be linked to an 
increased risk of OAC.    
Limited work has been done, however to identify risk factors for OAC in hens.  
One OAC risk factor that hens have in common with women is age.  Previous reports 
indicate that the prevalence of OAC in hens increases with bird age14-17. Chickens with 
higher plasma estradiol concentrations and larger ovaries were at significantly increased 
risk for OAC44.  In addition to the known risk factors for OAC in hens, genetics, flock 
husbandry and management practices, and history of exposure to pathogens should all be 
explored as potential risk factors. If additional risk factors are identified for hens, related 
factors could be investigated for women. These may be important determinants of the 
appropriateness of the hen as a human OAC research model. 
 
Oncogenic Viruses. The occurrence of a viral infection and the subsequent development 
of cancer is not new.  There are several examples in medicine of viral infections that 
induce cancer.    Examples include: Bovine and Feline Leukemia Viruses, Rous Sarcoma 
Virus, Marek’s Disease Virus, and Avian Leukosis Virus (ALV). In people, Human 
Papilloma Virus, Hepatitis Virus, Epstein-Barr Virus, Human Immunodeficiency Virus-1, 
and Human T-cell Lymphotropic Virus are all associated with the development of cancer.   
 Recently, human endogenous retroviruses (HERVs) have been identified as being 
associated with OAC.  Wang-Johanning and colleagues6 reported that the expression of 
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HERV-K env mRNA was greater in ovarian epithelial tumors than in normal ovarian 
tissues.  In addition, other classes of HERVs were also detected in the same ovarian 
cancer tissues.   
 Viruses, particularly retroviruses, can contribute to oncogenesis by transduction 
of oncogenes, Cis and Trans activation of host genes, direct stimulation of cell growth by 
viral envelope proteins or retrovirus-mediated immunosuppression9. The polymerase 
(pol) region of the retrovirus is responsible for encoding the viral enzymes required for 
replication, e.g. reverse transcriptase for  transcription of viral RNA into DNA, RNAse 
for removal of the RNA strand from the RNA-DNA double strand, integrase for 
integration of the virus into the host cell genome, and protease for proteolytic cleavage of 
the primary translation products9.  The specific pathogenesis of several viral induced 
cancers has been described in detail in the literature.  
 Bovine Leukemia Virus (BLV) is a C-type oncogenic retrovirus belonging to the 
deltaretrovirus genus. It affects cattle and sheep and leads to a neoplastic proliferation of 
polyclonal B lymphocytes in a disease known as bovine enzootic leukosis. It is mainly 
horizontally transmitted via mechanical blood transfer. It is thought to induce 
oncogenesis by way of the viral Tax protein, which functions as a transcription factor 
regulating the expressions of both viral and host genes. 
 Feline Leukemia Virus (FeLV) belongs to the gammaretrovirus genus and 
includes three genotypes: FeLV A, B, and C. It affects cats and is spread by both vertical 
and horizontal transmission. It causes aplastic anemia, immunodeficiency syndrome, T-
cell lymphoma and myeloid leukemia. The determinants of oncogenicity have been 
mapped to the U3 region of the long terminal repeat (LTR)9. 
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  Rous Sarcoma Virus belongs to the alpharetrovirus genus and affects chickens. 
The Rous Sarcoma Virus (RSV) genome has terminal repeats enabling its integration into 
the host genome and also over-expression of its genes69. The src gene is oncogenic and it 
triggers uncontrolled growth in abnormal host cells. It is an acquired gene, found to be 
present throughout the animal kingdom with high levels of conservation among species69. 
The src gene is taken up by RSV and incorporated into its genome conferring it with the 
advantage of being able to stimulate uncontrolled mitosis of host cells, providing 
abundant cells for fresh infection. The src gene is not essential for RSV proliferation but 
it greatly increases virulence when present69. 
 Viral hepatitis-induced hepatic cancer in humans is caused by chronic infection 
with hepatitis B and C, which are horizontally transmitted. Hepatitis B is caused by a 
hepdna virus (a DNA virus), and Hepatitis C is caused by a hepacivirus (an RNA virus)70.  
Both viruses induce cancer by causing mutations in the p53 gene70.  
 Like BLV, human T-cell lymphotropic virus (HTLV-1, Adult T-cell Leukemia, 
tropical spastic paraparesis) belongs to the deltaretrovirus genus. It affects humans and is 
transmitted by breast feeding, sexual contact, and transfusion of contaminated blood71. 
There are three main subtypes: acute, which has a poor prognosis, and chronic and 
smoldering, both of which have guarded prognoses. Its oncogenicity is primarily 
attributed to the action of the viral Tax protein, which regulates viral gene transcription 
by interacting with enhancer elements of the U3 region of the viral 5’ LTR45. Tax is also 
responsible for regulating other cellular genes, thus impairing cellular homeostasis 46-47. 
 It has been theorized that endogenous retroviruses, were once harmful, infectious 
retroviruses that became established in the genome. Endogenous retro viruses have a 
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similar structure to infectious retroviruses. The Murine Leukemia Virus (MLV) for 
example has the typical genome structure of simple retroviruses, of which there are 4 
genes: gag - encodes the viral core structural proteins; pro - encodes the viral protease; 
pol - encodes the viral enzymes including reverse transcriptase; and env which encodes 
the glycoproteins of the viral envelope.  
The retroviral genome is bounded at each end by long terminal repeats (LTRs) 
that regulate viral gene transcription. Each LTR contains unique 3’ (U3), repeat (R) and 
unique 5’ (U5) elements. ‘Unique’ refers to the sequences being only at one end (3’ or 5’) 
of viral genomic RNA, whereas U3 and U5 are present at both ends of proviral DNA. 
The repeat is a short sequence (15–250 nucleotides) repeated at the 3’ and 5’ ends of both 
viral genomic RNA and proviral DNA. The primer-binding site (PBS) is close to the 50 
LTR and is used by a specific transcription RNA (tRNA) molecule to initiate reverse 
transcription. Proviruses were disabled by mutations inhibiting the expression of proviral 
genes, causing them to evolve into harmless “junk” DNA over thousands of years48. 
Infectious retroviruses stimulate the cells in which they are expressed and enable the 
virus to evade an immune response by producing several accessory proteins that aid viral 
replication. Endogenous retroviruses possess the potential to express similar proteins and 
thus can become pathogenic. They can induce pathology in three ways. They can alter the 
immune system by suppressing it or stimulating it, by expressing accessory proteins that 
can directly affect infected cells, or they can disrupt genes at the integration sites48. 
Moyes et. al 48 proposed that genetic polymorphisms may be the answer as to how genes 
can cause disease in certain populations. They theorize that HERVs have polymorphisms 
that could affect the function of an expressed product. Insertionally polymorphic HERVs 
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are proviruses that are present only in a proportion of the human population. They are 
more likely to be pathogenic because their recent insertion might disrupt host genes, as 
the enhancer elements of retroviral LTRs can influence expression of neighboring 
cellular genes; as recent integrations, polymorphic HERVs are more likely to have 
retained functional coding sequences with the capacity to modulate cellular proliferation 
or the immune response48.  
 Denesvre10 demonstrated successfully the high sequence homologies and similar 
functional properties between endogenous ALV-J (ev/J 4.1 Rb) and ALV-J (exogenous 
infectious virus). This indicated that that the recent emergence of exogenous infectious 
ALV-J viruses is most likely due to re-combinational insertion of the ev/J endogenous 
sequences. They were also able to demonstrate that both the endogenous ev/J 4.1 Rb and 
exogenous ALV-J exhibited complete and full reciprocal interference to superinfection, 
indicating that they shared the same receptor. This may also be a possibility for ALV-E 
or other endogenous viruses in the chicken genome.  Huda11 found 11 new families of 
endogenous retroviruses in the Gallus Gallus genome. These new families occupy about 
2% of the chicken genome. These endogenous viruses can interact with any number of 
events to cause disease. ALV-E may be just one of them.   
 Although laying hens develop OAC with histologic features and epidemiological 
characteristics that are consistent with human OAC, an association with a viral risk factor 
similar to that found in humans has yet to be established in hens.  Fredrickson15 
conducted  a 3.5 year study that investigated the incidence of reproductive tract neoplasia 
in specific pathogen free (SPF) White Leghorn flocks and discovered that 32%  (149 of 
466) developed ovarian tumors, with 8% (39) being oviductal tumors and 5% (22) being 
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benign leiomyomas of the suspending ligament of the oviduct. Overall 45% of the birds 
had tumors of the reproductive tract. Occurrence was unusual in birds less than 2 years of 
age, and the dominant neoplasia type was malignant OAC (24%).   The hens used in this 
study were classified as free of ALV based upon the results of COFAL tests.  COFAL is 
a complement fixation test for detection of group specific ALV antigens49. However, 
interpretation of COFAL test results must consider that the COFAL test requires a large 
amount of antigen and may suffer from interference by other substances50.  When 
compared to other methods of ALV diagnosis, COFAL proved to be relatively insensitive 
and its findings did not correlate well with the other tests50.  These limitations in the 
validity of COFAL test results may be even more pronounced when attempting to detect 
endogenous ALV virus compared to the exogenous subtypes.  Fredrickson’s finding of a 
high prevalence of OAC in birds that were COFAL negative for ALV does not support 
the hypothesis that an endogenous ALV may be an important risk factor for OAC.  
However the validity of this conclusion is now questionable given the relative 
insensitivity of the test and its questionable ability to detect the endogenous virus.  As 
previously described, ALV has been associated with several types of sarcoma in 
chickens. 
 Avian Leukosis Virus was discovered in 1908 in Copenhagen9. The ALV are 
alpharetroviruses that are both horizontally and vertically transmitted.  The ALV env 
gene encodes a polyprotein that is processed into two glycoproteins: gp85env and 
gp37env. Variation in the nucleotide sequences of gp85env define the ALV subgroups A, 
B, C, D, and E 51-55. These subgroups cause neoplastic diseases such as B-cell 
lymphoma/leukemia, occasionally erythroleukemia (erythroblastosis) or myeloid 
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leukemia (myeloblastosis or myelocytomatosis).  Sporadically they may cause connective 
tissue tumors (fibrosarcoma, nephroblastoma, etc.)7-8. They act oncogenically through the 
mechanism of promoter/enhancer insertion or by transduction of an oncogene. Many 
currently known proto-oncogenes were first identified as parts of rapidly transforming 
ALVs (myc, myelocytoma; erb, erythroblastosis; myb, myeloblastosis; src,sarcoma, 
etc.)56. Subgroup J contains sequences homologous to both endogenous and exogenous 
viral elements56-58. ALV-J has been observed with increasing mortality in adult birds with 
myeloid leukosis and tumor infiltration and enlargement of the liver, spleen, kidneys and 
other organs13.  
  Oncogenic and exogenous Avian Leukosis/sarcoma groups A,B, C, and D are 
both horizontally and vertically transmitted in chickens,  whereas subgroup E viruses are 
described as non-oncogenic, endogenous viruses that are transmitted vertically  in  a non-
infectious form in a Mendelian fashion along with host genes 59-60. However, this 
characterization as non-oncogenic may need to be reconsidered in light of the recent 
discovery of multiple human endogenous retrovirus (HERV) envelope proteins in 
association with OAC in women6. The discovery of an analogous association between 
endogenous ALV-E and OAC in hens would further validate the chicken as a valid 
research model for human OAC. 
 The domestic hen is one of only a few species in which spontaneous OAC occurs 
at a prevalence similar to that seen in women.  Histopathologically, the tumors in hens 
and humans are very similar and similar tissue markers are expressed. Recently, Wang-
Johanning6 and colleagues reported a possible association between human endogenous 
retrovirus K (HERV-K) and OAC in women.  Expression of the HERV-K env mRNA 
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was greater in ovarian epithelial tumors than in normal ovarian tissues, and other classes 
of HERVs were also expressed in the same ovarian cancer tissues. An association was 
demonstrated, but no causal relationship has been established.  Identification of a 
retroviral etiologic agent responsible for the development of OAC would represent a 
major paradigm shift.  However, demonstration of a causal relationship between 
endogenous retroviruses and OAC will require experimental manipulation of a suitable 
animal model. It is plausible that endogenous retroviruses may be associated with OAC 
in domestic chickens, but no such association has been reported in the current literature.  
 Thus, the next logical step would be to identify a relationship between a viral risk 
factor, endogenous or otherwise, with OAC in hens. The current study examines the 
presence of ALV and expression of a partial gp85env for ALV-E as risk factors for OAC 
in hens.  
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Chapter 3.  Avian Leukosis Virus and Ovarian 
Adenocarcinoma in Hens 
Introduction 
 Laying hens spontaneously develop OAC with histologic features, biomarker 
staining and epidemiological characteristics similar to those seen in women.  These 
similarities have resulted in the hen being proposed as a suitable animal model for human 
OAC.  Recently, HERVs have been found to be associated with ovarian cancer in 
women6.  However, no viral risk factor has yet been identified in association with OAC 
in laying hens.  ALV-E is an endogenous retrovirus of chickens that maybe analogous to 
HERV’s in humans.  The identification of an association between OAC in hens and an 
endogenous retrovirus risk factor would further validate the use of the hen as a model for 
human OAC and facilitate research into the pathogenesis of OAC.  The goal of this study 
is to assess the association between OAC in laying hens and ALV infection in general 
and ALV subgroup E in particular. 
 
Materials and Methods  
Study Population: The study population was composed of 177 hens of > 100 weeks of 
age obtained from the UIUC Poultry Research Laboratory. This flock of laying hens 
consists of White Leghorn laying hens being reared in standard commercial caged-layer 
conditions.  There are three age strata of caged laying hens in the subset of the flock that 
is above 100 weeks of age: 104 weeks, 130 weeks and 165 weeks or older.  A pilot study 
was conducted to determine the prevalence of OAC and ALV in the flock.  Serology, 
bacteriology, necropsies, and histopathology were conducted on a sample of thirty 165 
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week old birds that had been selected to be culled from the flock.  The data obtained from 
the pilot study were used to establish the final sample size for the overall project.   
 Preliminary analysis of the data from the pilot study indicated that a total of 160 
birds would be required to detect an association between ALV seropositivity and OAC at 
80% power with 95% confidence.  Therefore, 147 hens from the UIUC Poultry Research 
Laboratory were obtained to supplement data from the 30 hens in the pilot study (total of 
177 hens). To ensure a representative sample of each age stratum, hens were selected 
using a random sampling technique. Laying hens at the UIUC Poultry Research 
Laboratory are housed in sections of cages with each section housing hens of the same 
age stratum. A random number list was generated in Microsoft Excel® that corresponded 
to the cage numbers. Each cage contained 4-6 hens of the same age. One hen was 
removed per cage.   A new random list was created for each sample collection session.  
Hens were transported to an on-farm necropsy room just prior to sampling. Blood was 
obtained via jugular or cardiac venipuncture. The blood was collected into anti-coagulant 
free glass tubes, using a 19- or 20-gauge 1-inch needle. Hens were then humanely 
euthanized in a carbon dioxide (CO2) chamber. Birds undergoing cardiac venipuncture 
were placed in the CO2 chamber for 1 min until unconscious before obtaining blood.  
Once euthanized, the hens were necropsied within 5 min. Birds were examined for gross 
lesions of the coelomic organs. The coelomic cavity was examined for excess fluid and 
the spleen was either placed in a cellophane bag on ice, or snap frozen with liquid 
nitrogen. Spleens were stored at -800 C, within 2 hrs of being harvested.  The ovaries and 
reproductive tract were examined grossly for tumors and placed in 10% buffered 
formalin. Other abdominal organs (liver, intestinal tract and kidneys) were examined for 
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evidence of metastasis. All tissues that appeared to be associated with tumors were 
harvested and placed in 10% buffered formalin.   
 Variables recorded for each hen included: age stratum (104 weeks, 130 weeks or 
165 weeks old); presence or absence of gross lesions; ALV ELISA test status; and  
presence or absence of OAC, based on histologic examination.  Data were stored in a 
Microsoft Excel®. Fisher’s Exact test, Χ2 analyses and multivariate logistic regression 
were used to determine associations between age stratum, ALV seropositive status, ALV-
Eenv mRNA expression and histologic confirmation of OAC. Odds ratios were used to 
describe the strength of these associations.  The statistical significance level was set at a p 
value of ≤0.05. 
 
Antigen Capture ELISA: Blood was allowed to clot, centrifuged at 8,000 x g for 15 min 
and the serum was pipetted into 5 ml polypropylene tubes (BD Falcon™A). Tubes were 
stored at -800 C. Serologic testing was conducted using a commercially-available antigen 
capture ELISA test to screen for ALV (IDEXX Flockchek LL Antigen test ®B
                                                 
A BD Falcon™. New Jersey USA 
) according 
to the manufacturer’s directions. The test detects antigen p27 which is common to all 
subgroups of ALV (A, B, C, D, E and J) and can be conducted on cloacal swabs, egg 
albumen, and serum. Serum samples are much more likely to detect endogenous ALV-E, 
while cloacal swabs tested with the antigen capture ELISA are more likely to detect 
exogenous ALV subgroups (A,B, C, D, and J)63. The tests were conducted using positive 
and negative controls provided by the manufacturer (contained in the test kit), and ELISA 
B IDEXX FLOCKCHEK Avian Leukosis Antigen Test Kit manual. Idexx Laboratories 
Maine USA 
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plates were read with a spectrophotometer (FLUOStar Optima microplate readerC
 
) at the 
absorbance value of 650 nm. The results were interpreted by the sample to positive (S/P) 
ratio, where an S/P ratio of ≤ 0.20 was considered negative.  An S/P ratio of > 0.20 
indicated presence of p27 antigen and was considered positive.  
Histopathology: The formalin-fixed tissues were trimmed, processed and stained with 
hematoxylin and eosin and examined for histologic evidence of OAC. Histologic 
classification of OAC was determined by the presence of numerous clumps or nests of 
dark staining epithelial cells supported by an underlying stroma of spindyloid cells. The 
epithelial cells may arrange themselves to form acini or tubules with round eosinophilic 
globules (ovalbumin) being present.  All tumors were examined histologically and 
classified according to their anatomical features as ovarian, oviductal or infundibular.  
 
RNA Extraction: The spleens were numbered according to the date and bird in the order 
that they were collected. Whole frozen spleens were broken at -800 C into pieces 
weighing 40 – 400mg (whole spleen weighed ~1.5 g). One piece from each spleen was 
placed into a 15 ml polypropylene tube of which 1 ml of Trizol®D was added per 100 mg 
of spleen. The suspension was then homogenized using a mechanical homogenizer 
(ULTRA-TURRAX T25 IKA®E
                                                 
C FLUOStar Optima microplate reader. Georgia USA. 
) until it was homogenous. Once the sample was 
homogenized, it was allowed to stand on the bench for 10 min at room temperature to 
allow Trizol® to digest the tissue at a maximum rate4. The homogenizer was washed 
D TRIzol® manual. Invitrogen products California USA  
E IKA®. Janke and Kunkel Staufen Germany 
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between samples with alcohol and water. After 10 min had elapsed, the sample was 
centrifuged at 4,500 x g for 5 min. After the centrifugation was complete, the sample was 
immediately placed on ice and 1.0 ml of the supernatant was transferred into a 1.5 ml 
polypropylene tube. Two hundred microliters of chloroform was then added to the tube. 
The suspension with the added chloroform  was then vortexed for 6 seconds (secs) 
followed by centrifugation at 16,000 x g at 40 C  for 20 min using an Eppendorf  5415 R 
centrifuge®F
 Centrifugation caused the sample to separate into 3 layers. The top layer 
contained RNA (clear), the middle layer protein (white) and the bottom layer DNA 
(sanguineous). Four hundred microliters of the supernatant containing the RNA was 
removed and placed into a new 1.5 ml polypropylene tube.  The remaining RNA 
supernatant along with some of the interface was removed and placed into a 0.5 ml 
polypropylene tube and centrifuged at 16,000 x g at 40 C for 10 min. Once centrifugation 
was complete, RNA (200µl) supernatant was again removed and added to the 
corresponding polypropylene tube to increase the quantity of RNA available.  
. 
 Nucleic acids were then precipitated with two hundred and fifty microliters of 
isopropanol.  The tubes were then inverted to mix the samples and the mixture was then 
stored overnight at -200 C. The Qiagen RNeasy RNA Clean up mini kit™G
  The 1.5 ml polypropylene tubes containing the RNA precipitate and isopropanol, 
were placed on ice and allowed to thaw on ice for ~ 30 min. Once thawed to liquid phase 
the samples were centrifuged at 16,000 x g at 4 0C for 30 min. The tubes, which now 
 was used to 
complete the RNA extraction procedure.  
                                                 
F  Eppendorf  5415 R® centrifuge. Eppendorf®  Hamburg  Germany 
G The Qiagen RNeasy RNA Clean up mini kit™.  Qiagen Products  California USA 
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contained pellets of RNA in a clear suspension then placed again on ice. Five hundred 
microliters of the supernatant was removed at a time with filter tipped pipettes.  Five 
hundred microliters of 100% ethanol was then added to the pellet and the tube was 
centrifuged placed at 40 C at 16,000 x g for 10 min. The liquid fraction comprised of 
water and alcohol was removed via a pipette. The tubes were then left to dry open on its 
side on the bench for 10 min.  One hundred microliters of diethylpyrocarbonate (DEPC) 
water was added to the dried RNA pellets. The mixture was then vortexed for 6 secs and 
placed in a water bath at 650 C for 5 min, vortexed again and re-placed in the water bath. 
This step was repeated for up to 20 min in the water bath to facilitate dissolving the RNA 
pellet.  
 Once dissolved, 350 µl of RLT Buffer™H was added. Once mixed, 250 µl of 
100% ethanol were added and mixed. Up to 700 µl of liquid mixture were then added to a 
spin column. The spin column was then centrifuged at 16,000 x g for 15 sec in a 
microcentrifuge (210 A Denville Scientific Inc.™I
 Five hundred microliters of RPE Buffer™8 (containing 100% ethanol) were added 
to the spin column, followed by centrifugation for 15 secs at 16,000 x g. The elute in the 
bottom tube was discarded. This step was repeated for a total of two washes. The spin 
column was then centrifuged at 16,000 x g for 2 min and the bottom collection tube was 
) The fluid in the bottom tube was 
discarded. Up to 700 µl of the liquid mixture were added again to the spin column, and 
the centrifugation and discard steps were repeated until the entire same sample was 
processed.   
                                                 
H The Qiagen RNeasy RNA Clean up mini kit™.  Qiagen Products  California USA 
I 210 A Denville Scientific Inc.™ New Jersey USA 
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removed and discarded altogether. The spin column was then placed into a new 1.5 ml 
polypropylene tube.  
 RNA was then eluted from the column by adding 150 μl of RNase free waterJ
 After priming the filter pipette tip, 4 µl of RNA-enriched fluid were added to 156 
µl of distilled water in a separate 1.5 ml polypropylene tube and mixed by pipetting.  The 
filter from the spin column was retained in the event that the amount of RNA was 
insufficient.  These RNA samples were diluted in distilled water were moved quickly to a 
spectrophotometer (Bio Rad Smart Spec™ 3000
  
were added, drop-by-drop, to each spin column just above the filter. The mixture was left 
to stand for 10 min on the bench and then centrifuged at 16,000 x g for 1 min in the 
microcentrifuge. The filtered fluid containing the RNA was transferred to a 1.5 ml 
polypropylene tube and placed on ice.  
K
 A sample with an A260 (260 nm) reading < 0.15 was considered to have an 
inadequate concentration of RNA. All samples with A260 > 0.7 were diluted with 
distilled water and re-measured. The ratio of A260 /A280 at neutral pH was used to 
indicate the quality of the RNA, with >1.5 indicating acceptable quality. The RNA 
samples were stored at -800 C.  The concentration for RNA was calculated according to 
the manufacturer’s directionsJ.  
). The spectrophotometer was blanked 
with 165 µl of distilled water. The water was then discarded and the sample placed in the 
cuvette and absorbance read at 260, 280 and 320 nm.  
                                                 
J The Qiagen RNeasy RNA Clean up mini kit™.  Qiagen Products  California USA 
K Bio Rad Smart Spec™ 3000  California USA 
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Reverse Transcription: Superscript ® III Reverse Transcriptase Invitrogen™ L
deoxyribonucleotide triphosphate 
 was used 
to conduct the reverse transcription. In a 1.5 ml polypropylene  tube 1 µl of 10mM 
mix (dNTP), 1 µl of random hexamers12, and 2 µg of 
sample RNA were made up to a total volume of 13 µl with double distilled water. The 
mixture was then placed in a water bath at 650 C for 5 min, chilled on ice for 1 min, and 
centrifuged for 15 secs, before adding 4 µl of 5X first strand buffer12, 1 µl of 0.1 M 
DTT12, 1 µl of Rnase out, and 1 µl of  SuperScript III12  were added. The mixture was 
then vortexed for 6 secs to facilitate mixing, and centrifuged for 15 secs. The tube was 
then placed in a water bath at 550 C  for 50 min, after which it was placed into another 
water bath at 700 C   for 15 min. Reverse transcription was considered complete at this 
point, with the product being complementary DNA (cDNA).  One hundred and eighty 
microliters of distilled water was then added to the tube to create a 1:10 dilution (20:180), 
mixed and the tube was mixed and stored at -800 C. 
  
Polymerase Chain Reaction: See Appendix C for primers. All primers designed by the 
investigators of this study was conducted using Primer3 Output11 software applied to the 
gp 85 env of the published complete sequence for ALV-E NSAC-1 in Genbank 
(Accession number FJ93550.1). Eukaryotic elongation factor 1 alpha (EFLα)  is a highly 
conserved gene that is highly expressed and  was used to check the quality of the cDNA .  
Sample #113 was chosen to be the positive control based on gross and histological 
evidence of OAC and ALV positive status on the ALV ELISA antigen test. Sample # 93 
was chosen as our negative control because of lack of gross and histological evidence for 
                                                 
L Superscript ® III Reverse Transcriptase. Invitrogen™  California USA 
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OAC and seronegativity on the ALV ELISA antigen test.  Initially, the published 
protocols for the primers PE1, PE2, PU1 and PU21 and ALV E and ALV All were 
adhered to and conducted on the positive control (sample #113), negative control (sample 
#93) and 10 samples.  However, these reactions did not reveal consistent results.  A 
gradient protocol was then initiated to test all the primers to determine the optimum 
annealing temperatures.  The crude primers were diluted in Tris- acetate EDTA buffer 
(TAE: 40 mM Tris-acetate: 1mM EDTA) to a concentration of 0.1 nmol/µl for storage at 
-800 C, and a further 1:10 dilution was made for use as the working stock. For example, 
40 nmol of crude primer was dissolved in 400 µl of TAE buffer for storage, and 20 µl of 
that stock was further diluted in 180 µl of distilled water to be used as the working stock. 
The working stock was then stored at -800 C.  
 The PCR assay included the following reagents in each reaction tube: 2.5 µl of 
10X Blue Juice™ M
 A gradient PCR was conducted for all the primers using our positive control 
cDNA (sample # 113) as the template. First, samples were denatured at 950 C for 30 secs. 
Then, samples were cycled 40 times as follows. All samples were denatured at 950 C for 
30 secs, then aliquots of template were annealed at one of five temperatures: 54.80 C, 
57.70 C, 60.30 C, 62.10 C, and 640 C, followed by an extension cycle at 720 C for 20 secs. 
 (Gel Loading Buffer), 1.0 µl of 50mM MgCl2, 0.5 µl of dNTP’s, 1.0 
µl (50pmol) of sense primer, 1.0 µl (50 pmol) of anitsense primer, 0.3 µlof Taq 
polymerase, 5 µl of template (cDNA from sample) and 13.7 µl of distilled water for a 
total volume of 25 µl.  
                                                 
M 10X Blue Juice™ . Invitrogen™ California USA 
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The final extension during the 40th cycle was performed for an additional 10 min. 
Samples were then incubated at 40 C until gel electrophoresis was performed.    
 
Results of the gradient PCR for primers: PE1, PE2, PU1, PU2 ALV E, ALV All, DIS1, 
DIS2, DISS1 or DISS2 yielded multiple bands of varying product sizes or no product 
evidenced by the absence of a band on the electrophoresis gels. However, for the ALV-E 
env and EF1α primers, it produced a bright single band of the appropriate size (215 bp for 
ALV-E env and 258bp for EF1α) across all temperatures, with the brightest band 
occurring at temperatures >620 C.  
 The following protocol was designed based on the optimum annealing 
temperature as indicated by the gradient, and the Primer 3 Output™ for the ALV-E env 
and EF1α primers. All samples were denatured at 950 C for 3 min. The samples were then 
cycled 4 times as follows. All samples were denatured at 950 C for 30 secs, annealed at 
620 C for 30 secs, followed by an extension cycle of 720 C for 27 secs. The samples were 
then cycled 41 times as follows. All samples were denatured at 95 0 C for 30 secs and 
then annealed at 620 C for 30 secs. The final extension was at 720 C for 10 min and then 
the samples were incubated at 40 C until gel electrophoresis was performed.  
 Once the DNA was amplified, electrophoresis was conducted on the product 
using 2% agarose gels. The gels were made by mixing 6g of agarose powder in 300 ml of 
Tris-EDTA buffer (TE buffer: 10 mM tris HCl :1 mM EDTA pH 8. Fifteen microliters of 
ethidium bromide were added to the gel in solution and left to set. Once the gel was set, it 
was immersed in TE buffer. The wells were checked for any cracks, breakage, collapse or 
leakage, visually and by adding 1 µl of 10X Blue Juice™ to each well. PCR tubes (0.2 
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ml) were pre-labeled to match the sample numbers that were placed in the PCR machine, 
and 1µl of 10X Blue Juice® was added to each tube. Ten microliters of DNA product 
from the PCR was added with a filter tip pipette tip to the corresponding 0.2 ml tube 
containing the 10X Blue Juice™ and mixed. The mixture was then loaded into the wells, 
one well per sample. One well on either end and in the middle of the gel was loaded with 
5 µl of 100bp ladder (Track it™ N).  The positive and negative controls were also loaded 
in two wells on the left. The ladders were loaded as such, to facilitate interpretation of the 
bands on the gels once the electrophoresis was complete. The gels were run at 120 mV, 
until the yellow dye of the ladder had run past the edge of the gel. Photographs of the gel 
were taken using Kodak MI™ systemO
 
. The digital images were printed and stored for 
analyses. A sample was considered positive if it produced a single bright band at the 
appropriate size according to the 100 bp ladder (Figures 5 and 6). The sample results 
were recorded for further analyses.  
Results  
  In the pilot sample of 30 birds that were 165 weeks of age, 18 birds were 
identified that were OAC positive based on histologic examination of the ovaries.  Birds 
with OAC were 2.6 times more likely to test positive for ALV using the IDEXX 
FlockChek antigen capture ELISA on serum samples collected prior to euthanasia, 
however in this small pilot study this association was not statistically significant 
(p=0.068).  There were no other associations between OAC and the occurrence of any 
other gross or histopathological lesions.  Post priori power analysis revealed that the 
                                                 
N Track it™  Invitrogen™ California USA 
O Kodak Molecular Imaging Software. Care Stream Health. Connecticut USA   
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sample of 30 hens with 18 cases and 12 controls had a statistical power of .23, indicating 
that the probability of Type II error was 77%.  Sample size calculations reveal that an 
additional 130 hens was required to achieve the target 80% statistical power.”  An 
additional 147 hens > 100 weeks of age were selected from the UIUC Poultry Research 
Laboratory using a stratified random procedure. 
 The overall prevalence of OAC was 22.6% (40/177) in the birds sampled, with a 
prevalence of 3.22% (1/31) in the 104 week stratum, 10.81% (4/37) in the 130 week 
stratum and 32.11% (35/109) in the 165 week stratum (Figure 3). The overall prevalence 
of ALV was 26.4% (42/159), with a prevalence of 43.3% (13/30) among hens in the 130 
week stratum and 29% (29/100) in the 165 week stratum.  No ALV positive hens were 
identified from the 104 week stratum. The overall prevalence for ALV-E env mRNA 
expression was 86.4% (108/125), with a prevalence of 77.8% (21/27) in the 104 week 
stratum, 100% (30/30) in the 130 week stratum and 83.8% (57/68) in the 165 week 
stratum (Figure 4).  Eighteen hemolyzed samples were removed from the analyses of the 
association between OAC and ALV. The presence of OAC was associated with the 
probability of being ALV positive (p<0.0001).  OAC-positive birds were 5.2 times more 
likely to be ALV positive (95% confidence interval (C.I.) 2.3, 11.18) (Table 1). Twenty-
two samples were removed from analysis of the association between OAC and ALV-E 
env mRNA expression due to inadequate RNA. Hens with OAC were 3.86 times more 
likely to express ALV-E env mRNA, but this was not significant (p=0.303) (Table 2).  
Hens expressing ALV-E env mRNA were 9.62 times more likely to be positive for ALV 
(p=0.040) (Table 3).  
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 OAC was associated (Χ2 = 15.2, p<0.0001) with age (Fig. 3).  Age stratum was 
also associated (Χ2 = 15.2 p=0.001) with ALV (Table 4). ALV positive hens were 
significantly more likely to be older.  Among the age strata, an association (Χ2= 6.81 
p=0.033) was observed between age and ALV-E env mRNA expression (Fig. 4). Since 
age was associated with OAC, ALV and ALV-E env mRNA expression, it was a 
potential confounder. Stratified analysis was conducted to control for the potential 
confounding affect of age. Analyses conducted within each stratum for OAC and ALV 
showed that for associations between ALV seropositivity and OAC, the only significance 
was found in the 165 week old stratum (p<0.001) (Tables 5-7). Also analyses conducted 
within the age stratum for associations between OAC and ALV-E env mRNA expression, 
showed that there was a trend toward significance at the highest age stratum  where hens 
that were ≥ 165 weeks old that  had OAC were 8.86 times  more likely to express ALV-E 
env mRNA, but this was not significant (p=0.056) (Tables 8-10).  
 The results of the multivariate logistic regression model are summarized in Table 
11.  Age stratum, ALV test status, and ALV-E env mRNA expression were introduced to 
the model.  All possible interactions between the independent variables were evaluated 
but no significant interactions were identified.   Age stratum and ALV test status were 
significantly associated with occurrence of OAC.  Controlling for ALV test status and 
ALV-E env mRNA expression birds with OAC had a 3.6% increase in odds of being in a 
higher age stratum (95% C.I. 1.0076, 1.0563).  Controlling for age stratum and Eenv 
mRNA expression, birds with OAC were 3.3 times more likely to be ALV positive (95% 
C.I. 1.1067, 10.1193).  The odds ratio of the association between OAC and ALV-E env 
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mRNA expression was of a similar magnitude (odds ratio = 3.2) however this association 
was not statistically significant (95% C.I. 0.3837, 27.4777) (Table 11). 
 
Discussion 
 The first objective of this study was to determine the prevalence of OAC, ALV, 
and ALV-E env mRNA expression in a stratified random sample of aged laying hens 
from the UIUC Poultry Research Laboratory.  The overall prevalence of OAC was 22.6% 
in this sample of birds with a trend of increasing prevalence with increased age.  This 
finding is consistent with the current literature on the epidemiology of OAC in both hens 
and women.  Frederickson15 reported that OAC was unusual in hens less than two years 
of age, with Rodriguez-Burford17 reporting the prevalence to be 4% among two-yr-old 
hens. In Frederickson’s study, 466 layers ranging from 2-7 years of age had an overall 
OAC prevalence of 19% and a trend of increasing prevalence with age: 12% at mean age 
3.9 years, 32% at mean age 4.2 years, and 50% at mean age 6.1 years. Other studies have 
also identified this relationship.16 In 4-yr-old birds, an OAC prevalence of 39% has been 
reported.14 In women, there is an age-related increase in incidence of OAC, from 0.7 per 
100,000 in women younger than 20-yrs to 6.6 at 20-49 yrs, 26.9 in women 50-64 years, 
48.6 in women 65-74 years and as high as 55.6 in women older than 75 years.64-66  
 The prevalence of ALV in the flock was similar to the OAC prevalence (26.4%).  
The prevalence of ALV was not uniform across age strata.  ALV-E is an endogenous 
retrovirus thought to be present within the genome of most domestic poultry.  In this 
sample the prevalence of ALV-E env mRNA expression in splenic tissue was 86.4%.  
Both ALV seropositive test status and ALV-E env mRNA expression were not uniformly 
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manifest across age strata, unlike the pattern of increasing prevalence with increased age 
that was demonstrated with the prevalence of OAC.  The 130 week age stratum had the 
highest prevalence of both ALV seropositive test status and ALV-E env mRNA 
expression (43.3% and 100% respectively).  The prevalence of both of these was lower in 
the 104 (ALV prevalence = 0 and ALV-E env mRNA expression prevalence = 77.8%) 
and 165 week age strata (ALV prevalence = 29% and ALV-E env mRNA expression 
prevalence = 83.8%). 
 The second objective was to assess the association between the presence of OAC 
and ALV seropositive status.  OAC-positive birds were 5.2 times more likely to be ALV 
positive (95% confidence interval (C.I.) 2.3, 11.18) (p<0.0001).  This was the first time 
that an association between OAC and a viral risk factor has been reported.  It is 
contradictory to earlier research by Fredrickson15  who reported a prevalence of OAC of 
24% in hens that had been classified as free of ALV based on the results of the COFAL 
test. The inconsistency between the results of the present study and that by Fredrickson 
and colleagues may be due to limited sensitivity of the COFAL test.  Other investigators 
have found COFAL proved to be a relatively insensitive diagnostic test for ALV and that 
the results did not correlate well with the other tests.50 These limitations may be even 
more pronounced when attempting to detect endogenous ALV virus compared with the 
exogenous subgroups.  COFAL detects the group specific ALV antigens that require 
culture, purification, titration and dilution for analysis, and is not used clinically for 
screen purposes 49-50. Whereas the ALV ELISA test kit which has a reported 99.2% 
sensitivity and 100% specificity and a detection limit of 2 ng, can be used clinically, with 
ease for screening for ALV .61-63 
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The third objective was to assess the association between presence of OAC and 
the expression of ALV-Eenv mRNA.   Across all age strata there was no association 
between OAC and expression of ALV-E mRNA expression (Odds ratio = 3.8, p = 0.303).  
However, when assessing the association between OAC and expression of ALV-E 
mRNA expression in the 165 week age stratum alone, despite the much smaller sample 
size, the odds ratio increased to 8.86 and the p value declined to 0.056.  While ALV-E 
env mRNA expression was common in both OAC positive and negative birds (Table 4), 
only 1 OAC positive bird failed to express ALV-E env mRNA.  This suggests that 
expression of ALV-E mRNA may be necessary for OAC to occur but perhaps not 
sufficient to cause OAC.  One possible explanation for this association may be that ALV-
E expression must have  to occur in the presence of an as yet unknown risk factor to 
cause disease. An alternative explanation may be that the site of ALV-E insertion into the 
genome may be an important risk factor for whether or not its presence induces OAC.  
Hens expressing ALV-E env mRNA were 9.62 times more likely to be positive for ALV 
(p=0.040).  The significant association between ALV-E env mRNA expression and ALV 
test status and their similar patterns of age distribution within the sample are not 
surprising since the antigen capture ELISA was detecting any subgroup of ALV and the 
RT-PCR was detecting ALV-E.   
 This study has identified important risk factors associated with the presence of 
OAC in aged laying hens. However, there are limitations inherent within the study 
design.  The cross-sectional nature of the study design precludes the establishment of a 
cause and effect relationship.  Age was associated with the presence of OAC, with ALV 
test status and ALV-E env mRNA expression.  Thus it is potentially an important 
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confounding variable. A prospective cohort study would be necessary to establish a 
temporal relationship between exposure to ALV (or ALV-E) and the subsequent 
development of OAC.  However this may prove difficult if endogenous ALV-E were to 
be included because it is considered ubiquitous in the chicken genome. 
 The strength of the associations reported in this study may have been reduced due 
to potential misclassification bias.  Ovarian tissues were evaluated in the same fashion 
across age strata.  OAC was diagnosed in this study based on the aforementioned 
histological criteria. Multiple sections of the each ovary were examined histologically, 
however the entire ovary for each bird was not examined.  As a result, small nests of 
neoplastic epithelial cells or tumors may have gone unrecognized causing OAC positive 
birds to have been misclassified as OAC negative.  Ideally the entire ovary should be 
examined. The large disparity between OAC prevalence in 130 week old birds and that in 
165 week old birds may be an indicator of misclassification error. This study reported the 
prevalence of OAC in 130 week old birds was one-third that found in 165 week old birds, 
from 10.81% in the 130 week old hens to 32.11% in the 165 week stratum.  It is 
reasonable to presume that a fraction of the 130 week old birds that appeared to be OAC 
negative on both gross and histological examination were actually in an early stage of 
OAC. 
 Determination of the association with ALV-E expression was accomplished using 
a primer for ALV-E env mRNA designed by the investigators.  A limited number of 
primers for the detection of ALV-E have been published.  However, those evaluated in 
this study did not produce products or produced products that yielded multiple bands of 
various sizes. This may have been due to errors in sample handling by the investigators.  
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Spleens may not have been frozen fast enough or handled in a manner to preserve the 
RNA, therefore yielding insufficient or poor quality RNA that was unsuitable for 
conducting the RT-PCR with those primers. Investigation into the melting temperatures 
for the sense and anti-sense of the published primers, showed a disparity of up to 10o C 
between a pair of complementary primers. This disparity can lead to a variety of 
nucleotide sequences being produced during the PCR reaction as the reaction 
temperatures increase and cool during the annealing stage. Some of the published primers 
had very large intended product sizes (>1.2 kb).  Large products lend themselves to 
interference from insufficient quantity or poor quality RNA.  This may result in vast 
variations in the intended product sequence as the primers are tested across different 
samples. This study contributes another primer for the detection of ALV-E. The Eenv 
primer designed here yielded a smaller product size with little disparity in annealing 
temperatures between the sense and antisense primers. Most importantly, the Eenv primer 
appeared to reliably produce appropriate products in the face of sub-optimum tissue 
handling for RNA extraction, while the other primers did not. 
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Chapter 4.  Conclusions and Future Directions 
 There were three objectives of this study.  
1. To determine the prevalence of OAC, ALV, and ALV-E mRNA expression in 
aged birds in the UIUC Poultry Research Laboratory. 
2. To determine the association between ALV serologic test status and OAC in aged 
birds in the UIUC Poultry Research Laboratory. 
3. To determine the association between expression of ALV-E env mRNA and OAC 
in aged birds in the UIUC Poultry Research Laboratory. 
  The study determined that the prevalence of OAC in the UIUC Poultry 
Research Laboratory in hens that were > 100 weeks of age was 22.6%  and that hens 
with OAC were significantly more likely to be older.  The prevalence of ALV was 
26.4% and that of ALV-E env mRNA expression was 86.4%.  ALV and ALV-E env 
mRNA expression were not uniformly distributed across the 3 age strata that were 
examined.  Hens in the >165 age stratum were more likely to be positive for both 
ALV and ALV-E env mRNA expression.  Hens with OAC were 5.2 times more likely 
to be ALV positive (p<0.0001).   While not statistically significant 165 week old hens 
that were OAC positive were 8.9 times more likely to expression ALV-Eenv mRNA 
(p=0.056).      
The identification of seropositive test status for ALV via antigen capture 
ELISA as a potential risk factor for OAC is an important new finding obtained from 
this study. This is the first time that a viral risk factor has been implicated as being 
associated with OAC in the hen.  Further research is needed to investigate the 
association between ALV-E and OAC in hens.  The findings from this study indicate 
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that at least one subtype of ALV may play a role in the pathogenesis of OAC in the 
hen.  If ALV-E is implicated as the important subgroup in the pathogenesis, then an 
endogenous retroviral association may indeed occur in both hens and women. 
  The associations between OAC, ALV and ALV-Eenv mRNA expression 
become particularly intriguing given the recently reported association between human 
endogenous retroviruses (HERVs) and human cancers48 including: breast cancer67 
colon cancer, germ cell tumors and prostate adenocarcinoma68.  Further 
experimentation is warranted to explore possible insertion sites, functional properties, 
and receptor sites for ALV –E and to distinguish them from other ALV subgroups.  
Because Avian Leukosis Virus subgroup E is an endogenous retrovirus of chickens 
that is analogous to HERVs in humans, our findings along with the theories of 
insertional polymorphisms, re-combinational insertion, and the massively unexplored 
new families of endogenous retroviruses within the chicken genome demands further 
investigation into the ongoing quest for a model for OAC in humans.  
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Appendix A.  Figures 
Figure 1. Diagram of the female reproductive tract of the hen21 
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Figure 2.  Gross appearance of ovarian adenocarcinoma in a 165 week old hen obtained 
from the University of Illinois Urbana-Champaign Poultry Research Laboratory laying 
flock. 
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Figure 3.   Prevalence of ovarian adenocarcinoma diagnosed by histologic examination 
in a stratified random sample of 177 White Leghorn hens obtained from the University of 
Illinois Poultry Research Laboratory laying flock. 
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Figure 4.  Prevalence of Avian Leukosis Virus subgroup E-env mRNA expression in a 
stratified random sample of 159 White Leghorn hens obtained from the University of 
Illinois Poultry Research Laboratory laying flock. 
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Figure 5.  Detection of Eukaryotic Translation Factor 1 alpha (EF1α) using primers EF1α 
1 and 2.  Lane “a” is the positive control. Lane “b” is the 100 bp ladder. Lanes “c” 
through “t” are PCR products from spleen samples of White Leghorn hens obtained from 
the University of Illinois Poultry Research Laboratory laying flock. Lane “u” is the 100 
bp ladder.  
 
 
 
a b c d  e  f   g  h  i  j   k  l  m  n  o  p  q  r  s  t  u   
248 bp 
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Figure 6.  Detection of Avian Leukosis Virus subgroup E env mRNA using primers Eenv 
1 and 2.  Lane “a” is the positive control. Lane “b” is the 100 bp ladder. Lanes “c” 
through “t” are PCR products from spleen samples of White Leghorn hens obtained from 
the University of Illinois Poultry Research Laboratory laying flock.  
 
 
 
a b c  d  e   f  g  h   i   j   k   l  m n  o  p  q   r  s   t    
215 bp 
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Appendix B.  Tables 
 
 
Table 1. Association between presence of ovarian adenocarcinoma (OAC) and of Avian 
Leukosis Virus (ALV) serologic test status in 159 White Leghorn hens > 100 weeks of 
age obtained from the University of Illinois Poultry Research Laboratory laying flock.  
 
 
 
  
ALV 
positive 
ALV  
negative 
21 
   19 
21 
98 
 
   OAC         OAC   Odds 
Positive      Negative  Ratio 
5.2 
Χ2 = 18.1, p<0.0001 
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Table 2. Association between presence of ovarian adenocarcinoma (OAC) and of Avian 
Leukosis Virus-E env mRNA expression (ALV-E) in 125 White Leghorn hens > 100 
weeks of age obtained from the University of Illinois Poultry Research Laboratory laying 
flock.  
 
 
 
 
    
ALV-E env 
positive 
 
 
ALV-E env 
negative 
  
21 
   1 
87 
16 
Fisher’s Exact p=0.303 
    OAC         OAC   Odds 
Positive     Negative   Ratio 
3.86 
 55 
Table 3. Association between Avian Leukosis Virus-E env mRNA expression (ALV-E) 
and presence of Avian Leukosis Virus determined by antigen capture ELISA of serum 
samples from 125 White Leghorn hens > 100 weeks of age obtained from the University 
of Illinois Poultry Research Laboratory laying flock.  
 
 
 
  
Eenv - Odds Ratio 
ALV + 
ALV - 
23 
   85 
 0 
17 
Fisher’s Exact p=0.04 
Eenv + 
9.62 
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Table 4. Association between age stratum and presence of Avian Leukosis Virus 
determined by antigen capture ELISA of serum samples from 159 White Leghorn hens > 
100 weeks of age obtained from the University of Illinois Poultry Research Laboratory 
laying flock.  
 
 
 Age      ALV      ALV 
Weeks   Positive   Negative 
    
Χ2 =15.2,  p< 0.001 
 
104 
130 
165 
   0 
    13 
29 
29 
  17 
71 
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Table 5.  Association between presence of ovarian adenocarcinoma (OAC) and of Avian 
Leukosis Virus (ALV) serologic test status in 29 White Leghorn hens in the 104 week 
age stratum obtained from the University of Illinois Poultry Research Laboratory laying 
flock.  
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 58 
Table 6. Association between presence of ovarian adenocarcinoma (OAC) and of Avian 
Leukosis Virus (ALV) serologic test status in 30 White Leghorn hens in the 130 week 
age stratum obtained from the University of Illinois Poultry Research Laboratory laying 
flock.  
 
 
    OAC              Odds 
Negative   Ratio 
ALV 
Positive 
ALV  
Negative 
3 
   10 
   1 
16 
Fisher’s Exact p=0.29 
  OAC 
Positive 
4.8 
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Table 7.  Association between presence of ovarian adenocarcinoma (OAC) and of Avian 
Leukosis Virus (ALV) serologic test status in 30 White Leghorn hens in the >165 week 
age stratum obtained from the University of Illinois Poultry Research Laboratory laying 
flock.  
 
  OAC               Odds 
Negative      Ratio 
ALV 
Positive 
ALV 
Negative 
18 
   17 
11 
54 
Χ2 =13.16 p <0.001 
OAC 
Positive 
5.2 
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Table 8. Association between presence of ovarian adenocarcinoma (OAC) and of Avian 
Leukosis Virus subgroup E env mRNA expression (ALV-E env) PCR status in 27 White 
Leghorn hens in the 104 week age stratum obtained from the University of Illinois 
Poultry Research Laboratory laying flock.  
 
 
Fisher’s Exact p=1.0
    OAC                   Odds 
Negative        Ratio 
ALV-E env  
positive 
ALV-E env 
negative  
1 
   0 
20 
6 
0.95 
  OAC 
Positive 
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Table 9. Association between presence of ovarian adenocarcinoma (OAC) and of Avian 
Leukosis Virus subgroup E env mRNA expression (ALV-E env) PCR status in 30 White 
Leghorn hens in the 130 week age stratum obtained from the University of Illinois 
Poultry Research Laboratory laying flock.  
 
    OAC          Odds 
Negative   Ratio 
ALV-E env 
positive 
ALV-E env 
negative 
4 
    0 
26 
0 
Fisher’s Exact p=1.0 
   OAC  
Positive 
0.17 
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Table 10.  Association between presence of ovarian adenocarcinoma (OAC) and of 
Avian Leukosis Virus subgroup E env mRNA expression (ALV-E env) PCR status in 68 
White Leghorn hens in the > 165 week age stratum obtained from the University of 
Illinois Poultry Research Laboratory laying flock.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  OAC  
Negative 
Odds 
Ratio 
ALV-E env 
positive 
ALV-E env 
negative 
17 
    0 
  41 
10 
Fisher’s Exact p=0.056 
OAC 
Positive 
8.86 
 63 
Table 11.   Logistic regression model considering age Stratum, Avian leukosis virus 
(ALV), and Avian Leukosis Virus subgroup E env (ALV-E env) mRNA expression in 
125 White Leghorn hens > 100 weeks of age obtained from the University of Illinois 
Poultry Research Laboratory laying flock.  
   
 
 
Variable               df        Coefficient      Standard     Odds        95% CI 
                                                                 Error          Ratio 
 Intercept 1 -8.1406    
 Age stratum 1 0.0349 0.0140 1.0355 1.0076,  1.0643 
 ALV ELISA 1 1.2079 0.5646 3.3465 1.1067, 10.1193 
 Eenv PCR 1 1.1778 1.0896 3.2472 0.3837, 27.4777 
 
Model Statistics: 
 
   df= 3;   Χ2= 14.5509;   p=0.0022 
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Appendix C.  Primers Used for ALV-E env mRNA detection 
 
 
 
 
Target Forward Primer (5’-3’) Reverse primer (5’-3’) Product  
(bp) 
Subgroup 
detection 
PU1/PU21 CTRCARCTGYTAGGYTCCCAGT GYCAYCACTGTCGCCTRTCCG 229 All 
PE1/PE21 GYCAYCACTGTCGCCTRTCCG GCACATCTCCACAGGTGTAAAT 265 ALV-E 
ALV all2 CGAGAGTGGCTCGCGAGATGG ACACTACATTTCCCCCTCCCTAT 2400 All 
ALV E2 CGAGAGTGGCTCGCGAGATGG GGCCCCACCCGTAGACACCACTT 1250 ALV-E 
DIS  GCGAGGAATGCAGGAAATTAC GGCATATTGCTGTGTCATCG 410 ALV-E 
DISS  CGCGTAACTGAGGGACTAGG GGCATATTGCTGTGTCATCG 159 ALV-E 
Eenv  TTTGGGGTCCTACAGCAAGAAT GTGAGCCAGAAGCAAGAAGTCA  215 ALV-E 
EF1α  CCCGAAGTTCCTGAAATCTG CTGAGGTGGCAGCTGATGTA 248  
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Appendix D.  Product Sequence for ALV-E env mRNA primer 
 
AGTCCAAAAGGTAGCAGCTGCGCAAGCCTTAAGAGAAATTGAGAGACTAGC
CTGTTGGTCCGTTAAACAGGCTAACTTGACAACATCACTCCTCGGGGACTTAT
TGGATGATGTCACGAGTATTCGACACGCGGTCCTGCAGAACCGAGCGGCTAT
TGACTTCTTGCTTCTGGCTCACAAAA 
 
